Cargando…
Emerging treatment strategies for metastatic triple-negative breast cancer
Triple-negative breast cancer (TNBC) is a heterogeneous subtype of breast cancer that is often associated with an aggressive phenotype and a poor prognosis. Cytotoxic chemotherapy remains the mainstay of treatment for most patients with metastatic TNBC (mTNBC), but duration of response is often shor...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9003656/ https://www.ncbi.nlm.nih.gov/pubmed/35422881 http://dx.doi.org/10.1177/17588359221086916 |
_version_ | 1784686176783826944 |
---|---|
author | Huppert, Laura A. Gumusay, Ozge Rugo, Hope S. |
author_facet | Huppert, Laura A. Gumusay, Ozge Rugo, Hope S. |
author_sort | Huppert, Laura A. |
collection | PubMed |
description | Triple-negative breast cancer (TNBC) is a heterogeneous subtype of breast cancer that is often associated with an aggressive phenotype and a poor prognosis. Cytotoxic chemotherapy remains the mainstay of treatment for most patients with metastatic TNBC (mTNBC), but duration of response is often short and median overall survival is only 12–18 months. Therefore, it is critical to identify novel treatment strategies to improve outcomes for these patients. In this review article, we discuss recent advances in treatment strategies for patients with mTNBC including the use of immune checkpoint inhibitors, targeted therapies, and antibody–drug conjugates. For each topic, we summarize important preclinical and clinical data, discuss implications for clinical practice, and highlight future research directions. |
format | Online Article Text |
id | pubmed-9003656 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-90036562022-04-13 Emerging treatment strategies for metastatic triple-negative breast cancer Huppert, Laura A. Gumusay, Ozge Rugo, Hope S. Ther Adv Med Oncol Review Triple-negative breast cancer (TNBC) is a heterogeneous subtype of breast cancer that is often associated with an aggressive phenotype and a poor prognosis. Cytotoxic chemotherapy remains the mainstay of treatment for most patients with metastatic TNBC (mTNBC), but duration of response is often short and median overall survival is only 12–18 months. Therefore, it is critical to identify novel treatment strategies to improve outcomes for these patients. In this review article, we discuss recent advances in treatment strategies for patients with mTNBC including the use of immune checkpoint inhibitors, targeted therapies, and antibody–drug conjugates. For each topic, we summarize important preclinical and clinical data, discuss implications for clinical practice, and highlight future research directions. SAGE Publications 2022-04-07 /pmc/articles/PMC9003656/ /pubmed/35422881 http://dx.doi.org/10.1177/17588359221086916 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Huppert, Laura A. Gumusay, Ozge Rugo, Hope S. Emerging treatment strategies for metastatic triple-negative breast cancer |
title | Emerging treatment strategies for metastatic triple-negative breast cancer |
title_full | Emerging treatment strategies for metastatic triple-negative breast cancer |
title_fullStr | Emerging treatment strategies for metastatic triple-negative breast cancer |
title_full_unstemmed | Emerging treatment strategies for metastatic triple-negative breast cancer |
title_short | Emerging treatment strategies for metastatic triple-negative breast cancer |
title_sort | emerging treatment strategies for metastatic triple-negative breast cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9003656/ https://www.ncbi.nlm.nih.gov/pubmed/35422881 http://dx.doi.org/10.1177/17588359221086916 |
work_keys_str_mv | AT huppertlauraa emergingtreatmentstrategiesformetastatictriplenegativebreastcancer AT gumusayozge emergingtreatmentstrategiesformetastatictriplenegativebreastcancer AT rugohopes emergingtreatmentstrategiesformetastatictriplenegativebreastcancer |